Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flow from operating activities:
Net loss	$ (19,754)	$ (22,013)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	1,834	2,156
Non cash lease expense	32	45
Provision for inventory obsolescence	(123)	(45)
Provision for credit losses	(61)	201
Change in fair value of warrant liabilities	(242)	8,875
Loss on issuance of common stock to Yorkville in connection with the Side Letter	149
Loss on issuance of common stock in connection with the settlement of debt	51
Stock-based compensation expense	2,637	2,966
Issuance of common stock to Palantir as consideration for settlement agreement		50
Issuance of common stock relating to Yorkville for debt extension and SEPA commitment fee		317
Loss on extinguishment of debt	5,736	3,908
Change in fair value of debt	12	(81)
Non cash interest expense	2,451	1,148
Other, net		181
Changes in assets and liabilities:
Accounts receivable	(1,350)	(3,924)
Inventory	2,550	3,181
Prepaid expenses and other assets	251	294
Accounts payable	17	(1,172)
Accrued expenses and other liabilities	2,709	1,171
Accrued R&D software		(1,800)
Lease liabilities — operating	83	88
Deferred revenue	25	51
Net cash used in operating activities	(2,993)	(4,403)
Cash flow from investing activities:
Capital expenditures		(39)
Net cash used in investing activities		(39)
Cash flow from financing activities:
Proceeds from warrants and short-term debt — related parties		15,000
Proceeds from issuance of common stock in connection with a warrant inducement	2,460
Repayments of short-term debt — unaffiliated		(17,374)
Proceeds from issuance of short-term debt — unaffiliated		2,993
Payment of SEPA commitment fee		(25)
Repayments of short-term debt — related parties	(42)	(10)
Proceeds from PIPE Offering, net of offering costs		6,000
Tax withholding on vesting of restricted stock units	(98)	(357)
Net cash provided by financing activities	2,320	6,227
Net (decrease) increase in cash, cash equivalents and restricted cash	(673)	1,785
Cash, cash equivalents and restricted cash at beginning of period	10,977	10,163
Cash, cash equivalents and restricted cash at end of period	10,304	11,948
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses		(11)
Contingent consideration reclassified to accrued expenses and other current liabilities	650
Deemed dividend relating to inducement of Dragasac warrants	64
Issuance and modification of C.V. Starr warrants in connection with forbearance		51
Issuance of RWI warrants in connection with forbearance		$ 1,223